CAS 1350462-55-3

Grazoprevir hydrate

Description:

Grazoprevir hydrate is an antiviral medication primarily used in the treatment of hepatitis C virus (HCV) infections. It belongs to the class of drugs known as NS3/4A protease inhibitors, which function by inhibiting the viral protease enzyme, thereby preventing the replication of the virus. The substance is characterized by its molecular formula, which reflects its complex structure, and it typically appears as a white to off-white solid. Grazoprevir is known for its high potency against various HCV genotypes and is often used in combination with other antiviral agents to enhance therapeutic efficacy and reduce the risk of resistance. Its solubility and stability are influenced by the presence of water in its hydrate form, which can affect its pharmacokinetic properties. As with many pharmaceuticals, it is essential to consider its safety profile, potential side effects, and interactions with other medications when used in clinical settings. Grazoprevir has been a significant advancement in the field of hepatitis C treatment, contributing to improved patient outcomes.

(33R,35S,91R,92R,5S)-5-(tert-Butyl)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-17-methoxy-4,7-dioxo-2,8-dioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopropanacycl

CAS: 1350462-55-3

(33R,35S,91R,92R,5S)-5-(tert-Butyl)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-17-methoxy-4,7-dioxo-2,8-dioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopropanacycl

Purity: 99%

Molecular weight: 784.93g/mol

Ref: 54-OR1065298

Grazoprevir hydrate

CAS: 1350462-55-3

Grazoprevir: Hepatitis C protease inhibitor effective against various genotypes, including drug-resistant strains.

Formula: C₃₈H₅₂N₆O₁₀S

Purity: 98%

Color and Shape: Solid

Molecular weight: 784.92

Ref: TM-T21456

Grazoprevir hydrate

CAS: 1350462-55-3

Grazoprevir hydrate is a direct-acting antiviral agent used in the treatment of hepatitis C virus (HCV) infections. It is a synthetic compound derived through targeted pharmaceutical synthesis aimed at inhibiting viral replication. This compound operates by selectively inhibiting the NS3/4A protease, an enzyme critically involved in the post-translational processing and replication of the HCV polyprotein. By blocking this protease, grazoprevir effectively disrupts the virus's life cycle, thereby reducing viral load in patients.

Formula: C₃₈H₅₂N₆O₁₀S

Purity: Min. 95%

Molecular weight: 784.9 g/mol

Ref: 3D-AEC46255